WELIREG DIN 02528908
Health Canada record
| Active ingredient(s) | BELZUTIFAN 40 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01XX74 BELZUTIFAN |
| Original market date | 01-Sep-2022 |
| Current status date | 01-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28568 | 2022-07-11 | New Drug Submission (NDS) |
International API supply for BELZUTIFAN
4 active FDA Drug Master Files.
Request a quote for WELIREG